Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New treatments for COPD.

Peter J Barnes1

  • 1National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London SW3 6LY, UK. p.j.barnes@ic.ac.uk

Nature Reviews. Drug Discovery
|July 18, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitochondrial dysfunction in lung ageing and disease.

European respiratory review : an official journal of the European Respiratory Society·2020
Same author

COPD 2020: new directions needed.

American journal of physiology. Lung cellular and molecular physiology·2020
Same author

Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study.

The Lancet. Respiratory medicine·2020
Same author

Hepcidin Is Essential for Alveolar Macrophage Function and Is Disrupted by Smoke in a Murine Chronic Obstructive Pulmonary Disease Model.

Journal of immunology (Baltimore, Md. : 1950)·2020
Same author

Sex and gender: modifiers of health, disease, and medicine.

Lancet (London, England)·2020
Same author

Virus-Induced Asthma Exacerbations: SIRT1 Targeted Approach.

Journal of clinical medicine·2020
Same journal

R&D productivity trends for biopharma companies in Asia and emerging markets.

Nature reviews. Drug discovery·2026
Same journal

Growth in clinical research capability in China and impact on the pharmaceutical sector.

Nature reviews. Drug discovery·2026
Same journal

Circular RNA guides exon skipping in DMD.

Nature reviews. Drug discovery·2026
Same journal

p38α inhibition restores axonal transport.

Nature reviews. Drug discovery·2026
Same journal

Inflammatory bowel disease-on-a-chip.

Nature reviews. Drug discovery·2026
Same journal

Designing GPCR-targeted miniproteins.

Nature reviews. Drug discovery·2026
See all related articles

Chronic obstructive pulmonary disease (COPD) is a growing global health concern with no current treatments to stop its progression. However, new drug targets are emerging from a deeper understanding of the disease's inflammatory and destructive processes, offering hope for future therapies.

Area of Science:

  • Pulmonology
  • Immunology
  • Pharmacology

Background:

  • Chronic obstructive pulmonary disease (COPD) is a leading global cause of morbidity and mortality.
  • The prevalence of COPD is increasing worldwide.
  • Current treatments do not halt the disease's progression.

Purpose of the Study:

  • To review the cellular and molecular mechanisms underlying COPD.
  • To identify novel therapeutic targets for COPD treatment.
  • To assess the prospects for new drug development in COPD.

Main Methods:

  • Literature review of cellular and molecular mechanisms in COPD.
  • Analysis of emerging therapeutic targets.
  • Evaluation of drug development pipelines for COPD.

Related Experiment Videos

Main Results:

  • Understanding of inflammatory and destructive processes in COPD has advanced.
  • Several novel molecular and cellular targets have been identified.
  • A number of drugs targeting these pathways are currently in development.

Conclusions:

  • Despite the lack of disease-modifying drugs, recent advances provide a strong basis for developing new COPD treatments.
  • The identification of novel targets offers promising prospects for halting COPD progression.
  • Ongoing drug development efforts hold potential for improved COPD management.